Xeris Biopharma (XERS)

Xeris’ commercial portfolio includes Gvoke, a ready-to-use glucagon product for severe hypoglycemia in people with diabetes; Keveyis, a treatment for primary periodic paralysis; and Recorlev, which is approved for endogenous hypercortisolemia in adults with Cushing’s syndrome when surgery is not an option or has not been curative. These products place the company in focused specialty markets where diagnosis, physician awareness, and patient support programmes are important parts of commercial execution.

A key part of Xeris’ identity is its formulation technology, including XeriSol and related non-aqueous systems. These technologies are intended to support stable, ready-to-use injectable medicines and may reduce the need for reconstitution, refrigeration, or more complex administration steps in certain products. The company uses this know-how both for internal development and as a basis for potential partnerships.

Its pipeline includes XP-8121, a once-weekly subcutaneous levothyroxine candidate that uses XeriSol technology and is aimed at patients who may benefit from an alternative to daily oral thyroid hormone therapy. Xeris therefore sits between a traditional specialty pharma business and a drug-delivery innovator. For investors following XERS, the main considerations include sales growth from its marketed products, progress of pipeline candidates, cash generation, and the company’s ability to expand the use of its proprietary formulation platform.